Research programme: atherosclerosis therapeutics - Genfit/Kowa
Latest Information Update: 22 Feb 2008
At a glance
- Originator Genfit; Kowa
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 22 Feb 2008 Discontinued - Preclinical for Atherosclerosis in France (unspecified route)
- 22 Feb 2008 Discontinued - Preclinical for Atherosclerosis in Japan (unspecified route)
- 05 Nov 2002 Preclinical trials in Atherosclerosis in France (unspecified route)